We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy 3 Medical Device Stocks for a Stable Portfolio With Solid Upside
Read MoreHide Full Article
Key Takeaways
ISRG benefits from rising procedure volumes, growing installations and broader robotic surgery applications.
STE gains from recurring healthcare demand, endoscopy share gains and pharmaceutical equipment demand.
PLSE advances its NPES platform across oncology, dermatology and minimally invasive treatments.
Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treatments.
Over the past several months, generative AI in the medical devices industry has moved from experimental to operational use. Applications include generating synthetic medical images, simulating disease progression, creating potential drug molecules and simulating their effects, to accelerate the long and costly drug development process.
The chart below shows the price performance of our three picks in the past month.
Image Source: Zacks Investment Research
Intuitive Surgical Inc.
Intuitive Surgical’s expanding installed base and procedure volumes underpin a business model with recurring instruments, accessories, lease and service revenues. Da Vinci 5 upgrades, single-port surgery and Ion lung biopsy broaden the platform's uses, while international markets offer room for greater adoption. Product innovation, training and digital tools may deepen ISRG’s hospital relationships and support utilization.
ISRG’s Ion creates exposure to diagnostic robotic-assisted procedures, separate from da Vinci's surgical applications. In 2025, Ion procedures increased approximately 51%, even as annual system placements declined from the preceding year, suggesting that greater use of installed equipment contributed to growth. By September 2026, the installed base had reached 1,152 units, up 21% year over year, and third-quarter Ion procedures grew 31%.
Strong Estimate Revisions
Intuitive Surgical has an expected revenue and earnings growth rate of 18.4% and 25.9%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.5% over the last 60 days.
ISRG has an expected revenue and earnings growth rate of 11.6% and 10%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 3.3% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 21.4% from the last closing price of $407.24. The brokerage target price is currently in the range of $324-$685. This indicates a maximum upside of 68.2% and a downside of 20.4%.
STERIS plc
STERIS benefits from recurring healthcare demand, endoscopy share gains and growth in consumables and services. Healthcare backlog is healthy, while renewed pharmaceutical investment lifts Life Sciences equipment demand. AST customer destocking has eased, although management cut its growth outlook.
Pricing supports STE’s profitability, but inflation and lower segment margins constrain operating leverage. Tariff refunds lifted recent earnings but are not expected to recur. The planned Xodus acquisition could expand STE’s recurring surgical sales while adding debt and integration risk. Chemistry capacity expansion and restructuring may improve efficiency but require investment.
Strong Estimate Revisions
STERIS has an expected revenue and earnings growth rate of 7.5% and 10.7%, respectively, for the current year (ending March 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 1.3% over the last 30 days.
STE has an expected revenue and earnings growth rate of 7.4% and 10.2%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 1.2% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 13.6% from the last closing price of $254.76. The brokerage target price is currently in the range of $270-$305. This indicates a maximum upside of 19.7% and no downside.
Pulse Biosciences Inc.
Pulse Biosciences operates as a novel bioelectric medicine company. PLSE is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling.
NPES provides effective local tumor control to initiate an adaptive immune response. PLSE deploys NPES platform applications which include human oncology, dermatology, aesthetics and other minimally invasive applications.
Strong Estimate Revisions
Pulse Biosciences has an expected revenue and earnings growth rate of more than 100% and -18.5%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.5% over the last 30 days.
PLSE has an expected revenue and earnings growth rate of more than 100% and -3.1%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 6.4% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 52.4% from the last closing price of $44.41. The brokerage target price is currently in the range of $60-$74. This indicates a maximum upside of 66.6% and no downside.
Image: Bigstock
Buy 3 Medical Device Stocks for a Stable Portfolio With Solid Upside
Key Takeaways
Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treatments.
Over the past several months, generative AI in the medical devices industry has moved from experimental to operational use. Applications include generating synthetic medical images, simulating disease progression, creating potential drug molecules and simulating their effects, to accelerate the long and costly drug development process.
Here, we recommend three stocks from the medical devices field with a favorable Zacks Rank to invest in for the rest of 2026. These are: Intuitive Surgical Inc. (ISRG - Free Report) , STERIS plc (STE - Free Report) and Pulse Biosciences Inc. (PLSE - Free Report) . Each of our picks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The chart below shows the price performance of our three picks in the past month.
Image Source: Zacks Investment Research
Intuitive Surgical Inc.
Intuitive Surgical’s expanding installed base and procedure volumes underpin a business model with recurring instruments, accessories, lease and service revenues. Da Vinci 5 upgrades, single-port surgery and Ion lung biopsy broaden the platform's uses, while international markets offer room for greater adoption. Product innovation, training and digital tools may deepen ISRG’s hospital relationships and support utilization.
ISRG’s Ion creates exposure to diagnostic robotic-assisted procedures, separate from da Vinci's surgical applications. In 2025, Ion procedures increased approximately 51%, even as annual system placements declined from the preceding year, suggesting that greater use of installed equipment contributed to growth. By September 2026, the installed base had reached 1,152 units, up 21% year over year, and third-quarter Ion procedures grew 31%.
Strong Estimate Revisions
Intuitive Surgical has an expected revenue and earnings growth rate of 18.4% and 25.9%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.5% over the last 60 days.
ISRG has an expected revenue and earnings growth rate of 11.6% and 10%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 3.3% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 21.4% from the last closing price of $407.24. The brokerage target price is currently in the range of $324-$685. This indicates a maximum upside of 68.2% and a downside of 20.4%.
STERIS plc
STERIS benefits from recurring healthcare demand, endoscopy share gains and growth in consumables and services. Healthcare backlog is healthy, while renewed pharmaceutical investment lifts Life Sciences equipment demand. AST customer destocking has eased, although management cut its growth outlook.
Pricing supports STE’s profitability, but inflation and lower segment margins constrain operating leverage. Tariff refunds lifted recent earnings but are not expected to recur. The planned Xodus acquisition could expand STE’s recurring surgical sales while adding debt and integration risk. Chemistry capacity expansion and restructuring may improve efficiency but require investment.
Strong Estimate Revisions
STERIS has an expected revenue and earnings growth rate of 7.5% and 10.7%, respectively, for the current year (ending March 2027). The Zacks Consensus Estimate for the current year’s earnings has improved 1.3% over the last 30 days.
STE has an expected revenue and earnings growth rate of 7.4% and 10.2%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 1.2% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 13.6% from the last closing price of $254.76. The brokerage target price is currently in the range of $270-$305. This indicates a maximum upside of 19.7% and no downside.
Pulse Biosciences Inc.
Pulse Biosciences operates as a novel bioelectric medicine company. PLSE is engaged in developing a novel and proprietary tissue treatment platform using Nano-Pulse Electro-Signaling.
NPES provides effective local tumor control to initiate an adaptive immune response. PLSE deploys NPES platform applications which include human oncology, dermatology, aesthetics and other minimally invasive applications.
Strong Estimate Revisions
Pulse Biosciences has an expected revenue and earnings growth rate of more than 100% and -18.5%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 4.5% over the last 30 days.
PLSE has an expected revenue and earnings growth rate of more than 100% and -3.1%, respectively, for the next year. The Zacks Consensus Estimate for next year’s earnings has improved 6.4% over the last 30 days.
Solid Price Upside
The short-term average price target of brokerage firms represents an increase of 52.4% from the last closing price of $44.41. The brokerage target price is currently in the range of $60-$74. This indicates a maximum upside of 66.6% and no downside.